These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15118261)

  • 1. Onset age is associated with outcome of radioiodine therapy in Graves' disease.
    Yamashita Y; Yamane K; Tamura T; Okubo M; Kohno N
    Endocr J; 2004 Apr; 51(2):127-32. PubMed ID: 15118261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome.
    de Bruin TW; Croon CD; de Klerk JM; van Isselt JW
    J Intern Med; 1994 Nov; 236(5):507-13. PubMed ID: 7964426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.
    Markovic V; Eterovic D
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3547-52. PubMed ID: 17609305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
    Haase A; Bähre M; Lauer I; Meller B; Richter E
    Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
    Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
    Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
    Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
    Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
    Uy HL; Reasner CA; Samuels MH
    Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease.
    Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT
    Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.